<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02544087</url>
  </required_header>
  <id_info>
    <org_study_id>2015DFA31130</org_study_id>
    <nct_id>NCT02544087</nct_id>
  </id_info>
  <brief_title>Heat-clearing and Blood-activating Chinese Medicinal Components in Acute Cerebral Infarction</brief_title>
  <official_title>Heat-clearing and Blood-activating Chinese Medicinal Components in Acute Cerebral Infarction: Mechanisms of Multi-target Anti-inflammatory Action</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yunling Zhang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shandong University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huairou Hospital of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dongfang Hospital Affiliated to Beijing University of Chinese Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study is designed to confirm the therapeutic effects of heat-clearing and
      blood-activating Chinese medicinal components in treatment of Acute Cerebral Infarction (ACI)
      and to investigate the therapeutic mechanisms of multi-target anti-inflammatory action
      involved from the standpoint of pathology, cell and molecular biology, as well as immunology.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The present study is designed to confirm the therapeutic effects of heat-clearing and
      blood-activating Chinese medicinal components in treatment of Acute Cerebral Infarction (ACI)
      and to investigate the therapeutic mechanisms of multi-target anti-inflammatory action
      involved from the standpoint of pathology, cell and molecular biology, as well as immunology.
      In particular, investigators choose heat-clearing Ixeris of sonchifolia Hance(Kudiezi
      Injection) and blood-activating Panax notoginseng saponins(Xueshuantong Injection)as the
      therapeutic interventions to carry out the investigation, applying the key techniques such as
      Lentivirus-mediated RNA interference, co-immunoprecipitation and immunomagnetic beads.

      With the joint efforts, investigators hope to find out the combined therapeutic targets based
      on better understanding of the inflammatory pathology in ACI and illuminate the synergistic
      mechanisms involved, which may validate the Chinese medicine theory of&quot;cerebral vascular
      damage due to heat toxicity&quot; in the pathogenesis of ACI and yield new therapeutic strategies
      for ACI. As an international science and technology cooperation project, the study is of
      great significance in establishing an international technology platform of intervention
      target system for the treatment of ACI; moreover, it marks a key step forward for China to
      enhance China's international brands through exploring a successful mode of foreign
      cooperation in Chinese medicine.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>modified Rankin scale</measure>
    <time_frame>180 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Barthel index</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>national institute of health stroke scale</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glasgow coma scale</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>scores of Chinese medicine symptoms</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality rate</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disability rate</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>The basic treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Comply to the Chinese guidlines of acute ischemic stroke in 2014</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clearing heat</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Treat with KDZ injection on the basis of basic treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Promoting blood circulaton</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Treat with Xueshuantong injection on the basis of basic treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clearing heat&amp;Promoting blood circulaton</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treat with both KDZ injection and Xueshuantong injection on the basis of basic treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ixeris of sonchifolia Hance</intervention_name>
    <description>KDZ40ml+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.</description>
    <arm_group_label>Clearing heat</arm_group_label>
    <other_name>KDZ injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panax notoginseng saponins</intervention_name>
    <description>Xueshuantong450mg+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.</description>
    <arm_group_label>Promoting blood circulaton</arm_group_label>
    <other_name>Xueshuantong injections</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ixeris of sonchifolia Hance combined with Panax notoginseng saponins</intervention_name>
    <description>KDZ40ml+0.9%N.S.250ml,ivdrip;Xueshuantong450mg+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.</description>
    <arm_group_label>Clearing heat&amp;Promoting blood circulaton</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with acute ischemic stroke

          -  Patients with fire-heat syndrome

          -  Stroke onset within 48 hours

          -  NIHSS scores range from 5 points to 25 points

          -  Age from forty to eighty,gender not limited

          -  Informed and signed the consent

        Exclusion Criteria:

          -  Cardiogenic cerebral embolism,stroke caused by other reasons or the unexplained

          -  Patients suitable for thrombolytic therapy(rt-PA,urokinase),or have recieved
             thrombolytic therapy

          -  Patients suitable for endovascular therapy,or have recieved endovascular therapy

          -  Patients with serious disease of heart,lungs,liver or kidneys（The value of ALT or AST
             is more than 2 times of the upper limit of normal range,the value of creatinine is
             more than 1.5 times of the upper limit of normal range，asthma or COPD,or cardiac
             function level 4）

          -  Patients with bleeding or bleeding tendency recently

          -  Pregnant or lactating women

          -  Pre-existing limb dysfunction, psychiatric diaseses，or cognitive dysfunction that
             could confound the study results

          -  Patients with allergic constitutions,or have the contraindication of Ixeris of
             sonchifolia Hance components(KDZ injection) or Panax notoginseng saponins
             components(Xueshuantong injection)

          -  Patients have participated in other clinical trials within 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yunling Zhang, PhD,MD</last_name>
    <role>Study Chair</role>
    <affiliation>Dongfang Hospital Affiliated to Beijing University of Chinese Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhang, PhD,MD</last_name>
    <phone>+86 10 67689634</phone>
    <email>yunlingzhang2004@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Neurology,Dongfang Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100078</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yunling Zhang, PhD,MD</last_name>
      <phone>+86 10 67689634</phone>
      <email>yunlingzhang2004@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurology,Huairou Hospital of Traditional Chinese Medicine</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>101400</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiyou Qi</last_name>
      <phone>+86 13716441030</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurology,Affiliated Hospital of Shandong University of Traditional Chinese Medicine</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xianghua Qi</last_name>
      <email>qixianghua2005@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurology,Wuqing Hospital of Traditional Chinese Medicine</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>301700</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dan Liu</last_name>
    </contact>
    <contact_backup>
      <phone>+86 15122068119</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2015</study_first_submitted>
  <study_first_submitted_qc>September 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2015</study_first_posted>
  <last_update_submitted>July 27, 2017</last_update_submitted>
  <last_update_submitted_qc>July 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Dongfang Hospital Affiliated to Beijing University of Chinese Medicine</investigator_affiliation>
    <investigator_full_name>Yunling Zhang</investigator_full_name>
    <investigator_title>President of Dongfang Hospital</investigator_title>
  </responsible_party>
  <keyword>fire-heat syndrome</keyword>
  <keyword>blood stasis syndrome</keyword>
  <keyword>method of clearing heat</keyword>
  <keyword>method of promoting blood circulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

